CMC & ManufacturingLast reviewed April 2026

Process Analytical Technology(PAT)

A framework for designing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes.

Usage Examples

NIR-based PAT provided real-time blend uniformity monitoring enabling continuous granulation control.
Real-time release testing per PAT eliminated end-product assay testing for the approved product.

What is PAT?

PAT is FDA's framework (2004 guidance) for building quality into pharmaceutical manufacturing through real-time analytical measurement of critical attributes during processing rather than relying solely on end-product testing. Integrated with ICH Q8 QbD, PAT uses in-line, on-line, or at-line process analyzers (NIR, Raman, HPLC, optical) to monitor CQAs continuously and enable real-time process adjustments.

PAT enables advanced manufacturing approaches: real-time release testing (RTRT), continuous manufacturing, and adaptive process control. It moves quality from a testing-based paradigm to a design-and-control paradigm. PAT systems require substantial upfront investment in analyzer qualification, method development, multivariate data analysis capabilities, and quality system integration. FDA's Emerging Technology Team provides support for novel PAT and continuous manufacturing applications.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH Q8, ICH Q13, FDA PAT GUIDANCE.

FDAICHHealth Canada

When This Matters

NIR-based PAT provided real-time blend uniformity monitoring enabling continuous granulation control.
Real-time release testing per PAT eliminated end-product assay testing for the approved product.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

ICH Q8ICH Q13FDA PAT GUIDANCE

Frequently Asked Questions

No. PAT is an optional framework for advanced process control. Traditional batch release testing remains fully acceptable. PAT is adopted when its efficiency and quality benefits justify the significant investment in analyzers, methods, and data infrastructure.

RTRT uses PAT-based in-process measurements to assess product quality continuously during manufacture, enabling release decisions without separate end-product testing. FDA approval of RTRT requires demonstrated equivalence to traditional release testing plus robust PAT infrastructure.

Continuous manufacturing requires real-time quality control — traditional sample-and-wait testing doesn't fit continuous flow. PAT provides the real-time measurement backbone. ICH Q13 (2022) codifies continuous manufacturing expectations; PAT adoption is effectively prerequisite.